查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2099673

醫藥及醫療設備組合產品市場－2026-2032年全球市場預測

Drug-Device Combination Products Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，醫藥和醫療設備市場合計將成長至 2,746.1 億美元，複合年成長率為 8.36%。

主要市場統計數據
基準年 2025 1564.6億美元
預計年份：2026年 1687億美元
預測年份 2032 2746.1億美元
複合年成長率 (%) 8.36%

藥物和醫療設備的組合產品處於藥品、生技藥品、醫療設備、數位健康和​​互聯醫療的交匯點。這些產品包括預填充式注射器、自動注射器、藥物釋放型支架、藥用貼片、吸入器、輸液系統、植入式藥物傳遞平台以及伴隨診斷療法，它們在精準醫療和以患者為中心的治療模式中扮演著日益重要的角色。它們的價值在於提高劑量準確性、依從性、安全性、易用性和治療效果，同時支持傳統臨床環境以外的醫療服務。

監管機構根據複雜產品的主要作用機制進行分類，申請者必須滿足藥品和醫療設備在品質、安全性、性能、人因工程、臨床證據、標籤、上市後監測和風險管理方面的要求。生技藥品、自行注射、微創手術和數位化療法的日益普及，使得藥品-醫療設備器材複合體的開發變得更加複雜，也更具戰略意義。為了滿足不斷變化的全球合規要求，行業相關人員優先考慮整合設計管理、藥品品質系統、生物相容性測試、萃取物和溶出度評估、可用性工程、網路安全和生命週期管理。

推動需求成長的因素包括慢性病管理、居家醫療、連網藥物傳輸設備、穿戴式注射器、智慧吸入器、預填充給藥系統和植入式治療設備。在糖尿病、腫瘤、心血管疾病、呼吸系統疾病、自體免疫疾病、疼痛管理和神經病學等治療領域，複雜的產品正在改變治療的給藥、監測和最佳化方式。

醫藥和醫療設備複雜產品領域的變革性變化

在醫藥和醫療設備領域，一場結構性變革正在發生，從以產品為中心的開發模式轉向整合的治療生態系統。傳統的醫療設備給藥方式正被互聯互通、以使用者為中心的平台所取代，這些平台融合了製劑科學、機械工程、軟體、感測器和實際性能監測。這種轉變在自行注射系統、穿戴式給藥設備、智慧吸入器和旨在減輕治療負擔並支持分散式醫療的數位化用藥依從性解決方案中尤為明顯。

人工智慧對複雜產品的累積影響

人工智慧（AI）對藥品和醫療設備的研發、生產、監管和臨床應用的影響日益顯著。在研發領域，AI驅動的建模可以輔助配方和醫療設備相容性分析、給藥模擬、失效模式評估以及醫療設備人體工學設計的最佳化。此外，機器學習工具正被探索用於分析人因資料、識別使用錯誤模式以及改進醫療設備使用說明書、訓練材料和病患支援計畫。

關於醫藥和醫療設備複雜產品的關鍵區域見解

亞太地區正逐漸成為醫藥和醫療設備的重要樞紐，這主要得益於醫療保健覆蓋範圍的擴大、慢性病盛行率的上升、生物製藥應用的日益普及，以及中國、印度、日本、韓國和澳洲等國強大的生產能力。區域監管機構持續加強對醫療設備和藥品的監管，鼓勵申辦方提供更清晰的證據資料，以證明產品的易用性、品質和臨床療效。對糖尿病護理、呼吸系統給藥系統、注射式癌症治療和家庭護理技術等醫療設備的需求，推動了預填充式注射器、自動注射器、穿戴式式注射器和互聯給藥平台的快速發展。

各主要團體對藥品及醫療設備合併的看法

在東協，隨著慢性病治療、生物製藥和醫療設備療法的普及，醫療保健系統的重要性日益凸顯。儘管東南亞各國致力於協調監管，以改善醫療設備註冊和藥品監管流程，但各國的具體要求仍十分重要。糖尿病、呼吸系統疾病和心血管疾病的日益增多，以及對私人醫療保健投資的增加，推動了市場需求，使得便捷易用的吸入器、預填充式注射器、自動注射器和攜帶式輸液系統具有重要的戰略意義。

各國對藥品和醫療設備複雜產品的洞察

美國憑藉其結構化的監管分類流程、強大的生物製藥研發管線、先進的臨床研究體係以及對自我給藥療法的旺盛需求，為製藥和醫療設備複合體的開發提供了主導。在加拿大，對安全性、品質、雙語標籤和循證審查流程的重視，正在推動生技藥品遞送系統和慢性病管理技術的擴張。在墨西哥，法律規範的加強，加上醫院和區域製造網路的不斷擴展，正在推動對糖尿病、呼吸系統疾病、心血管疾病和注射療法的需求。

為行業領導者提供的實用建議

產業領導者應從早期概念階段就優先考慮整合開發計劃，確保在達到關鍵開發里程碑之前，配方、醫療設備設計、軟體組件、包裝、標籤、人因工程和生產要求等方面保持一致。尤其當產品包含數位功能、感測器、連接功能或伴隨診斷時，儘早進行監管分類並與相關監管機構協調可以降低不確定性。

調查方法

本執行摘要採用系統的二手研究途徑編寫，重點關注與藥品和醫療設備複雜產品相關的、檢驗的公共領域和行業認可的資訊來源。該調查方法包括對監管指南、衛生監管機構出版刊物、醫療設備和藥品品質標準、同行評審文獻、臨床實踐趨勢、公共衛生數據以及與複雜產品開發、藥物輸送系統、人體工學、互聯醫療設備和上市後監測相關的政策文件的審查。

結論

隨著治療方式向精準給藥、自我給藥、互聯監測和整合式患者支持方向發展，藥物和醫療設備的結合在現代醫療保健中變得至關重要。這一演變是由生物製藥的成長、慢性病管理的需求、數位醫療的普及、日益成長的監管壓力以及對更安全、更便捷的治療體驗的需求共同推動的。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：醫藥及醫療設備組合產品市場：依產品類型分類

  • 藥物釋放型支架
  • 吸入器
  • 注射系統
    • 自動注射器
    • 無針注射器
  • 預填充式注射器和筆式注射器
  • 外用藥物
  • 經皮貼劑

第8章：醫藥及醫療設備組合產品市場：依技術分類

  • 先進的釋放技術
  • 可生物分解技術
  • 傳統製藥和醫療設備的聯合技術
  • 智慧型裝置技術
    • 自動化管理
    • 數位監控

第9章：藥品與醫療設備組合產品市場：依劑型分類

  • 液體
  • 半固態製劑
    • 奶油
    • 軟膏
    • 粉末
  • 固態劑型
    • 膠囊
    • 藥片

第10章：醫藥及醫療設備聯合產品市場：依治療領域分類

  • 心血管藥物
  • 糖尿病/內分泌學
  • 荷爾蒙補充療法
  • 抗癌藥物
    • 化療
    • 參與式癌症治療
  • 疼痛管理

第11章：醫藥及醫療設備組合產品市場：依最終用戶分類

  • 門診手術中心
  • 居家照護環境
  • 醫院和診所
  • 專科診所

第12章：醫藥及醫療設備組合產品市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：醫藥及醫療設備綜合產品市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：藥品和醫療設備綜合產品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • B. Braun SE
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Braile Biomedica
  • Cardinal Health, Inc.
  • CODAN Companies
  • Cook Group Incorporated
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi
  • ICU Medical, Inc.
  • InSitu Technologies Inc.
  • JMS North America Corporation
  • Lepu Medical Technology Company
  • Medtronic PLC
  • MicroPort Scientific Corporation
  • Novartis AG
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • SOOIL Developments Co., Ltd.
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Group
  • Viatris Inc.
  • WL Gore & Associates Inc.
Product Code: MRR-742BD517D8D5

The Drug-Device Combination Products Market is projected to grow by USD 274.61 billion at a CAGR of 8.36% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 156.46 billion
Estimated Year [2026] USD 168.70 billion
Forecast Year [2032] USD 274.61 billion
CAGR (%) 8.36%

Drug-device combination products sit at the intersection of pharmaceuticals, biologics, medical devices, digital health, and connected care. These products, including prefilled syringes, autoinjectors, drug-eluting stents, medicated patches, inhalers, infusion systems, implantable drug delivery platforms, and companion diagnostic-enabled therapies, are increasingly central to precision medicine and patient-centric treatment models. Their value lies in improving dose accuracy, adherence, safety, usability, and therapeutic outcomes while supporting care delivery beyond traditional clinical settings.

Regulatory agencies classify combination products based on the product's primary mode of action, requiring sponsors to address both drug and device expectations across quality, safety, performance, human factors, clinical evidence, labeling, post-market surveillance, and risk management. Rising use of biologics, self-administered injectables, minimally invasive procedures, and digitally enabled therapies has made drug-device combination product development more complex and strategically important. Industry stakeholders are prioritizing integrated design controls, pharmaceutical quality systems, biocompatibility testing, extractables and leachables assessment, usability engineering, cybersecurity, and lifecycle management to meet evolving global compliance requirements.

Demand drivers include growth in chronic disease management, home-based healthcare, connected drug delivery devices, wearable injectors, smart inhalers, prefilled delivery systems, and implantable therapeutic devices. Across therapeutic areas such as diabetes, oncology, cardiovascular disease, respiratory care, autoimmune disorders, pain management, and neurology, combination products are reshaping how therapies are administered, monitored, and optimized.

Transformative Shifts in the Drug-Device Combination Products Landscape

The drug-device combination products landscape is undergoing a structural shift from product-centric development toward integrated therapeutic ecosystems. Traditional device-assisted drug delivery is being replaced by connected, user-focused platforms that combine formulation science, mechanical engineering, software, sensors, and real-world performance monitoring. This shift is particularly visible in self-injection systems, wearable drug delivery devices, smart inhalers, and digital adherence solutions designed to reduce treatment burden and support decentralized care.

Regulatory expectations are also transforming the sector. Authorities increasingly emphasize early determination of product classification, robust combination product quality systems, device design validation, human factors studies, clinical usability evidence, and post-market risk monitoring. The convergence of pharmaceutical good manufacturing practices with medical device quality management standards is pushing organizations to create cross-functional development teams that include regulatory affairs, clinical development, engineering, pharmacovigilance, human factors, software quality, and supply chain specialists.

Another major shift is the move toward lifecycle-based product strategy. Sponsors are designing platforms that can support multiple drug formulations, enable dose flexibility, reduce administration errors, and generate adherence or performance data. Sustainability is also gaining attention as inhaler propellants, single-use plastics, sharps disposal, and device recyclability come under greater scrutiny. Together, these changes are increasing the strategic importance of combination product governance, risk-based evidence generation, and global regulatory harmonization.

Cumulative Impact of Artificial Intelligence on Combination Products

Artificial intelligence is increasingly influencing the development, manufacturing, regulation, and clinical use of drug-device combination products. In research and development, AI-enabled modeling can support formulation-device compatibility analysis, dose delivery simulations, failure mode evaluation, and optimization of device ergonomics. Machine learning tools are being explored to analyze human factors data, identify patterns in use errors, and improve device instructions, training materials, and patient support programs.

In manufacturing and quality control, AI can enhance process monitoring, predictive maintenance, visual inspection, anomaly detection, and root-cause analysis across highly regulated production environments. For combination products that require tight integration between a drug container closure system and a delivery device, AI-supported analytics can help detect variability in assembly performance, injection force, dose accuracy, seal integrity, and component defects. These capabilities align with broader industry movement toward continuous verification, digital quality management, and data-driven risk control.

AI also has growing relevance in connected drug delivery devices. Smart inhalers, injection platforms, and wearable systems can generate data on timing, dose events, technique, and adherence. When governed appropriately, AI can help transform this data into actionable insights for patients, clinicians, and care teams. However, the cumulative impact of AI depends on validated algorithms, transparent data governance, cybersecurity safeguards, bias mitigation, privacy compliance, and regulatory alignment. For industry leaders, the immediate opportunity is not only automation, but the creation of safer, more personalized, and more measurable therapeutic experiences.

Key Regional Insights for Drug-Device Combination Products

Asia-Pacific is becoming a critical hub for drug-device combination products due to expanding healthcare access, rising chronic disease prevalence, increasing biologics adoption, and strong manufacturing capabilities in countries such as China, India, Japan, South Korea, and Australia. Regional regulators continue to strengthen medical device and pharmaceutical oversight, encouraging sponsors to build clearer evidence packages for usability, quality, and clinical performance. Demand for diabetes care devices, respiratory drug delivery systems, oncology injectables, and home-based treatment technologies is supporting broader adoption of prefilled syringes, autoinjectors, wearable injectors, and connected delivery platforms.

North America remains one of the most advanced regions for combination product development, supported by mature regulatory pathways, high uptake of biologics and specialty medicines, established clinical research infrastructure, and strong demand for self-administration and connected care. The United States has a highly developed framework for product classification, human factors engineering, current good manufacturing practice expectations, and post-market monitoring, while Canada continues to align device and drug oversight with patient safety and quality requirements. The region's emphasis on decentralized care and chronic disease management is strengthening interest in smart injectors, inhalation systems, implantable drug delivery devices, and digital adherence technologies.

Latin America is evolving as access to advanced therapies, biosimilars, and device-enabled treatment options improves across major healthcare systems. Brazil and Mexico are particularly relevant due to their regulatory modernization efforts, hospital infrastructure expansion, and growing chronic disease burden. Adoption is shaped by reimbursement conditions, public procurement priorities, import dependencies, and local registration requirements. Combination products that improve treatment adherence, reduce hospital visits, and simplify administration are gaining attention in diabetes, respiratory care, cardiovascular therapy, and oncology support.

Europe has a sophisticated regulatory environment shaped by medical device regulation, pharmaceutical quality requirements, notified body involvement, and strong pharmacovigilance systems. The region places significant emphasis on clinical evidence, safety, post-market surveillance, usability, and sustainability. Drug-device combination products in Europe are influenced by growing demand for biologic drug delivery, prefilled systems, inhalers, transdermal technologies, and implantable therapeutic devices. Environmental considerations, including inhaler emissions and device waste, are increasingly relevant to product design and procurement decisions.

The Middle East is experiencing rising interest in advanced drug delivery and connected healthcare as governments invest in specialty care, hospital modernization, diabetes management, and digital health infrastructure. Gulf countries are advancing regulatory capabilities and procurement models that favor high-quality, clinically validated technologies. Combination products that enable outpatient care, chronic disease self-management, and improved medication adherence are becoming more important as healthcare systems respond to noncommunicable disease burdens and population health goals.

Africa presents a diverse and developing landscape for drug-device combination products, with adoption influenced by healthcare infrastructure, affordability, supply chain resilience, training needs, and regulatory capacity. Opportunities are most visible in essential drug delivery, respiratory therapy, infectious disease care, maternal health, diabetes management, and injectable medicines where ease of use and stability are essential. Regional progress depends on stronger regulatory harmonization, local distribution networks, healthcare worker training, and product designs suited to varied care environments.

Key Group Insights for Drug-Device Combination Products

ASEAN is gaining importance as healthcare systems expand access to chronic disease treatment, biologics, and device-enabled therapies. Regulatory convergence efforts across Southeast Asia are improving pathways for medical device registration and pharmaceutical oversight, although country-specific requirements remain important. Demand is supported by rising diabetes, respiratory disease, cardiovascular conditions, and growing private healthcare investment, making user-friendly inhalers, prefilled syringes, autoinjectors, and portable infusion systems strategically relevant.

The GCC is advancing combination product adoption through healthcare modernization, digital health investment, and national strategies focused on chronic disease management and specialty care. Countries in the group are building more sophisticated regulatory and procurement systems, with emphasis on quality, international standards, and clinical value. Drug-device combination products that support self-administration, remote monitoring, and outpatient treatment align well with regional healthcare transformation priorities, particularly in diabetes, obesity-related conditions, respiratory care, oncology, and cardiovascular disease.

The European Union represents a highly regulated and evidence-driven environment for combination products, shaped by strict medical device requirements, pharmaceutical standards, clinical evaluation expectations, and post-market surveillance obligations. Developers must address interactions between medicinal product authorization and device conformity assessment, especially for integral drug-device combinations. The EU's focus on patient safety, traceability, real-world evidence, and sustainability is influencing product design, documentation, and lifecycle management strategies.

BRICS countries collectively reflect a broad mix of manufacturing strength, healthcare demand, regulatory evolution, and access challenges. China and India are major drivers due to their scale, local production capabilities, and increasing adoption of advanced drug delivery technologies. Brazil and South Africa highlight the importance of public health access, affordability, and procurement efficiency, while Russia maintains demand for localized and resilient healthcare supply chains. Across BRICS, combination products that balance performance, cost, manufacturability, and regulatory compliance are especially relevant.

The G7 continues to shape global standards for drug-device combination product innovation through advanced regulatory systems, strong clinical research infrastructure, high biologics utilization, and mature pharmacovigilance and device vigilance frameworks. These economies are central to the development of connected drug delivery, smart inhalers, autoinjectors, implantable drug delivery devices, and software-enabled adherence platforms. Their regulatory and reimbursement expectations often influence evidence strategies used in other regions.

NATO member countries include many advanced healthcare systems with strong emphasis on supply chain security, medical readiness, regulatory quality, and interoperability of health technologies. While NATO is not a healthcare regulatory body, member countries' focus on resilience and preparedness has relevance for injectable therapies, emergency-use delivery systems, pain management products, antidote delivery devices, and portable treatment technologies. Combination products that are reliable, easy to train, stable in varied environments, and compatible with secure logistics can support broader health system resilience.

Key Country Insights for Drug-Device Combination Products

The United States is a leading environment for drug-device combination product development due to its structured regulatory classification process, strong biologics pipeline, advanced clinical research ecosystem, and high demand for self-administered therapies. Canada emphasizes safety, quality, bilingual labeling, and evidence-based review processes, with growing use of biologic delivery systems and chronic disease management technologies. Mexico is strengthening regulatory oversight while demand rises for diabetes, respiratory, cardiovascular, and injectable therapies supported by hospital expansion and regional manufacturing connections.

Brazil is a major Latin American environment for advanced drug delivery due to its large public and private healthcare systems, chronic disease burden, and ongoing regulatory modernization. The United Kingdom maintains strong capabilities in clinical research, health technology assessment, digital health, and device-enabled medicines, with particular interest in usability, patient adherence, and care pathway efficiency. Germany is highly influential in Europe due to its medical technology base, strict quality expectations, advanced hospital systems, and demand for biologics, prefilled syringes, infusion systems, and connected care solutions.

France combines robust healthcare coverage, strong pharmacovigilance expectations, and interest in patient-friendly delivery technologies for chronic and specialty diseases. Russia's combination product environment is shaped by localization priorities, supply chain resilience, and demand for injectable and hospital-based therapies. Italy and Spain are important European healthcare systems where aging populations, chronic disease management, and public procurement dynamics influence demand for inhalers, prefilled delivery systems, transdermal products, and infusion technologies.

China is rapidly advancing in drug-device combination products through regulatory reforms, domestic innovation, large-scale manufacturing, and growing adoption of biologics and specialty medicines. India is expanding as both a manufacturing base and a demand center, with relevance in affordable injectable delivery, respiratory devices, biosimilars, and chronic disease care. Japan is characterized by high quality expectations, an aging population, sophisticated device engineering, and strong demand for safe, precise, and user-friendly delivery systems.

Australia has a well-developed regulatory and healthcare environment with interest in home-based care, digital health, and chronic disease management technologies. South Korea is increasingly important due to its advanced medical technology sector, digital health capabilities, biologics manufacturing strength, and demand for connected, high-performance drug delivery platforms. Across these countries, successful strategies depend on aligning product design, regulatory evidence, local usability needs, reimbursement pathways, and supply chain execution.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated development planning from the earliest concept stage, ensuring that drug formulation, device design, software components, packaging, labeling, human factors, and manufacturing requirements are aligned before pivotal development milestones. Early regulatory classification and engagement with relevant authorities can reduce uncertainty, especially when products include digital features, sensors, connectivity, or companion diagnostics.

Organizations should strengthen combination product quality systems by bridging pharmaceutical quality requirements with medical device design controls, risk management, supplier qualification, process validation, complaint handling, and post-market surveillance. Human factors engineering should be treated as a core development discipline rather than a late-stage validation activity, particularly for self-administered, wearable, inhaled, or implantable products.

Leaders should also invest in data governance and cybersecurity for connected drug delivery products. As devices generate adherence and performance data, manufacturers need validated analytics, privacy safeguards, secure software updates, and clear responsibilities across the product lifecycle. Supply chain resilience is equally critical, including dual sourcing of critical components, container closure integrity assurance, and robust monitoring of electronics, polymers, needles, sensors, and sterile components.

Commercial and clinical teams should focus on demonstrable value: reduced administration errors, improved adherence, fewer clinic visits, better patient experience, and measurable therapeutic support. Evidence generation should include usability data, real-world performance insights, patient-reported outcomes, and health system workflow benefits where appropriate. Finally, sustainability should be embedded into product design through material selection, device recyclability, lower-waste packaging, and responsible end-of-life planning.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified public-domain and industry-recognized sources relevant to drug-device combination products. The methodology includes review of regulatory guidance, healthcare authority publications, medical device and pharmaceutical quality standards, peer-reviewed literature, clinical practice trends, public health data, and policy documents related to combination product development, drug delivery systems, human factors engineering, connected medical devices, and post-market surveillance.

The analysis prioritizes data-backed insights from recognized regulatory and healthcare institutions, including guidance on product classification, design controls, current good manufacturing practice expectations, biocompatibility, usability engineering, software lifecycle management, cybersecurity, pharmacovigilance, and device vigilance. Regional, group, and country insights are synthesized from documented healthcare infrastructure trends, regulatory developments, chronic disease burden indicators, biologics adoption patterns, digital health initiatives, and medical technology manufacturing capabilities.

No market sizing, market share estimation, revenue forecasting, or speculative numerical projection is included. The research framework emphasizes qualitative evidence, regulatory context, clinical relevance, technology adoption, patient safety, and operational implications. Insights are cross-checked for consistency across multiple source categories to support reliable executive-level interpretation.

Conclusion

Drug-device combination products are becoming essential to modern healthcare as therapies move toward precision dosing, self-administration, connected monitoring, and integrated patient support. The sector's evolution is being shaped by biologics growth, chronic disease management needs, digital health adoption, regulatory rigor, and demand for safer, more convenient treatment experiences.

The most successful stakeholders will be those that manage combination products as unified therapeutic systems rather than separate drug and device components. This requires early regulatory strategy, strong quality integration, human-centered design, validated manufacturing processes, cybersecurity readiness, and lifecycle evidence generation. Regional differences in regulation, infrastructure, reimbursement, and patient access will continue to influence adoption patterns, making localization and compliance planning critical.

Artificial intelligence, connected devices, and real-world data have the potential to improve development efficiency, product reliability, adherence, and clinical decision support. However, their impact depends on responsible validation, transparent governance, and patient trust. As healthcare systems seek better outcomes outside traditional care settings, drug-device combination products will remain a high-priority innovation area for pharmaceutical, medical device, and digital health stakeholders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug-Device Combination Products Market, by Product Type

  • 7.1. Introduction
  • 7.2. Drug-Eluting Stents
  • 7.3. Inhalers
  • 7.4. Injector Systems
    • 7.4.1. Auto-Injectors
    • 7.4.2. Needle-Free Injectors
  • 7.5. Prefilled Syringes & Pens
  • 7.6. Topical Medicines
  • 7.7. Transdermal Patches

8. Drug-Device Combination Products Market, by Technology

  • 8.1. Introduction
  • 8.2. Advanced Release Technologies
  • 8.3. Biodegradable Technology
  • 8.4. Conventional Device-Drug Technology
  • 8.5. Smart Device Technologies
    • 8.5.1. Automatic Dosing
    • 8.5.2. Digital Monitoring

9. Drug-Device Combination Products Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. Liquid Dosage Forms
  • 9.3. Semi-Solid Dosage Forms
    • 9.3.1. Creams
    • 9.3.2. Ointments
    • 9.3.3. Powders
  • 9.4. Solid Dosage Forms
    • 9.4.1. Capsules
    • 9.4.2. Tablets

10. Drug-Device Combination Products Market, by Therapeutic Class

  • 10.1. Introduction
  • 10.2. Cardiovascular Medications
  • 10.3. Diabetes & Endocrinology
  • 10.4. Hormonal Replacement Therapy
  • 10.5. Oncology Drugs
    • 10.5.1. Chemotherapy
    • 10.5.2. Participatory Oncology Treatment
  • 10.6. Pain Management

11. Drug-Device Combination Products Market, by End-User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Homecare Settings
  • 11.4. Hospitals and Clinics
  • 11.5. Specialty Clinics

12. Drug-Device Combination Products Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Drug-Device Combination Products Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Drug-Device Combination Products Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. AbbVie Inc.
  • 16.3. B. Braun SE
  • 16.4. Baxter International Inc.
  • 16.5. Becton, Dickinson and Company
  • 16.6. BIOTRONIK SE & Co. KG
  • 16.7. Boston Scientific Corporation
  • 16.8. Braile Biomedica
  • 16.9. Cardinal Health, Inc.
  • 16.10. CODAN Companies
  • 16.11. Cook Group Incorporated
  • 16.12. F. Hoffmann-La Roche Ltd.
  • 16.13. Fresenius Kabi
  • 16.14. ICU Medical, Inc.
  • 16.15. InSitu Technologies Inc.
  • 16.16. JMS North America Corporation
  • 16.17. Lepu Medical Technology Company
  • 16.18. Medtronic PLC
  • 16.19. MicroPort Scientific Corporation
  • 16.20. Novartis AG
  • 16.21. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 16.22. SOOIL Developments Co., Ltd.
  • 16.23. Stryker Corporation
  • 16.24. Teleflex Incorporated
  • 16.25. Terumo Group
  • 16.26. Viatris Inc.
  • 16.27. W. L. Gore & Associates Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG-ELUTING STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG-ELUTING STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG-ELUTING STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INHALERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INJECTOR SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INJECTOR SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INJECTOR SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTO-INJECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTO-INJECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTO-INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEEDLE-FREE INJECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREFILLED SYRINGES & PENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PREFILLED SYRINGES & PENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREFILLED SYRINGES & PENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TOPICAL MEDICINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TOPICAL MEDICINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TOPICAL MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADVANCED RELEASE TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADVANCED RELEASE TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADVANCED RELEASE TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIODEGRADABLE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIODEGRADABLE TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIODEGRADABLE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONVENTIONAL DEVICE-DRUG TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONVENTIONAL DEVICE-DRUG TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONVENTIONAL DEVICE-DRUG TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SMART DEVICE TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SMART DEVICE TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SMART DEVICE TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATIC DOSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATIC DOSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATIC DOSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIGITAL MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIGITAL MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIGITAL MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SEMI-SOLID DOSAGE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SEMI-SOLID DOSAGE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SEMI-SOLID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CREAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OINTMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OINTMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OINTMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POWDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POWDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POWDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIOVASCULAR MEDICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOVASCULAR MEDICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOVASCULAR MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIABETES & ENDOCRINOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIABETES & ENDOCRINOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIABETES & ENDOCRINOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HORMONAL REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HORMONAL REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HORMONAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PARTICIPATORY ONCOLOGY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PARTICIPATORY ONCOLOGY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PARTICIPATORY ONCOLOGY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 191. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 192. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 193. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 219. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 224. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 225. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 226. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 230. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 235. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 236. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 237. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 256. CANADA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. CANADA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 258. CANADA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 259. CANADA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 264. MEXICO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. MEXICO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. MEXICO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 267. MEXICO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. MEXICO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 269. MEXICO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 270. MEXICO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 271. MEXICO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 275. BRAZIL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. BRAZIL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. BRAZIL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 278. BRAZIL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. BRAZIL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 280. BRAZIL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED KINGDOM DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 297. GERMANY DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. GERMANY DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. GERMANY DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 300. GERMANY DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. GERMANY DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 302. GERMANY DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 303. GERMANY DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 304. GERMANY DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 305. GERMANY DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 306. GERMANY DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 308. FRANCE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. FRANCE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. FRANCE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 311. FRANCE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 312. FRANCE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 313. FRANCE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 314. FRANCE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 315. FRANCE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 316. FRANCE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 317. FRANCE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 318. FRANCE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 319. RUSSIA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. RUSSIA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. RUSSIA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 322. RUSSIA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 323. RUSSIA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 324. RUSSIA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY